UCB (OTCMKTS:UCBJF) Shares Gap Up - What's Next?

Key Points

• Shares gapped up: UCB opened at $296.54 versus a prior close of $279.95 (about a 5.9% jump) but with very light reported volume (33 shares traded).
• Positive analyst sentiment: Six analysts rate the stock a Buy and firms including Goldman Sachs, Barclays, Stephens and Wolfe Research have reiterated buy/overweight or initiated coverage with Outperform.
• Company profile & technicals: UCB is a Belgium-based biopharma focused on immunology and neurology, trading near its 200-day SMA ($296.67) while its 50-day SMA is $309.06, and showing moderate leverage (debt/equity 0.33) with modest liquidity (current ratio 1.19, quick ratio 0.78).

UCB SA (OTCMKTS:UCBJF - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $279.95, but opened at $296.54. UCB shares last traded at $296.54, with a volume of 33 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on UCBJF shares. The Goldman Sachs Group reiterated a "buy" rating on shares of UCB in a research note on Monday, February 16th. Stephens reiterated an "overweight" rating on shares of UCB in a research report on Thursday, January 15th. Barclays reiterated an "overweight" rating on shares of UCB in a research note on Tuesday, January 6th. Finally, Wolfe Research began coverage on shares of UCB in a research report on Monday, February 23rd. They set an "outperform" rating on the stock. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy".

UCB Trading Up 5.9%

The company has a fifty day simple moving average of $309.06 and a two-hundred day simple moving average of $296.67. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB's work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.